Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kindstar Globalgene Technology, Inc. ( (HK:9960) ) has shared an announcement.
Kindstar Globalgene Technology, Inc. has announced that its subsidiary, Wuhan Kindstar, has successfully acquired a 40% equity interest in Huaxi Kindstar from Huaxi Health Technology for RMB12,396,000. This acquisition, which was completed through a public tender, is considered a connected transaction under the Hong Kong Stock Exchange’s listing rules but is exempt from certain requirements due to its size. The acquisition is expected to strengthen Kindstar’s position in the market by expanding its stake in Huaxi Kindstar, potentially enhancing its operational capabilities and market influence.
The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.
More about Kindstar Globalgene Technology, Inc.
Average Trading Volume: 720,001
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.31B
See more data about 9960 stock on TipRanks’ Stock Analysis page.